Trial Profile
Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA Association
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms SENIOR
- 12 Dec 2023 Results comparing Synthetic control arms (SCA) with real-world (RW) data treated by anti-CD20+miniCHOP in LNH03-7B and LNH09-7B along with SENIOR trial, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Apr 2021 Status changed from active, no longer recruiting to completed.
- 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology